Milestone Payment Triggered by Initiation of Additional Preclinical Studies for REV102, a Potential First-in-Class Oral ENPP1 Inhibitor for Hypophosphatasia –– Extends Cash Runway through 2027 –NEW ...

Rallybio (RLYB) announced that it received an equity milestone payment of $12.5M from Recursion Pharmaceuticals (RXRX). The milestone payment was ...

Hamilton, Bermuda, September 11th, 2025, ChainwireOnRe, an onchain asset manager delivering institutional-grade yield to ...

Forbes contributors publish independent expert analyses and insights. I write about the business of healthcare. This article is more than 4 years old. Chris Gibson, Co-Founder & CEO, Recursion ...

Autonomous AI agents are more than just extensions of vendor tools. They’re credentialed actors who connect and execute, and ...

OnRe launched OnRe Points, a rewards program designed to incentivize meaningful participation in the ONyc ecosystem.

Recursion Pharmaceuticals has significantly lagged the market since its 2021 IPO. The company's potentially revolutionary approach has yet to produce results. The stock's upside is enormous if ...

Recursion Pharmaceuticals has significantly lagged the market since its 2021 IPO. The company's potentially revolutionary approach has yet to produce results. The stock's upside is enormous if ...

Self-Referential Large Models: Recursive Self-Enhancement in Code Generation ...

We recently published 10 Stocks Crash as AI Glow Fades. Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) is one of Wednesday’s worst performers. Recursion Pharmaceuticals dropped for a third straight day ...